Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott LabsfiledCriticalAbbott Labs
Publication of ECSP034612ApublicationCriticalpatent/ECSP034612A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Uso de agonista selectivos del receptor de dopamina D4 y composiciones que contienen agonista selectivos del receptor de dopamina D4 para el tratamiento de la disfunción sexual.Use of selective dopamine D4 receptor agonist and compositions containing selective dopamine D4 receptor agonist for the treatment of sexual dysfunction.
ECSP0346122000-11-222003-05-19
USE OF DOPAMINE D4 RECEIVER SELECTIVE AGONIST TO TREAT SEXUAL DYSFUNCTION
ECSP034612A
(en)
Use of bacillus subtilis qst713 nrrl b-21661 to formulate a probiotic composition for an animal; and probiotic composition of bacillus subtilis qst713 nrrl b-21661.
COMPOUNDS DERIVED FROM REPLACED PIRIDINONES; ITS USE IN THE TREATMENT OF AFFECTIONS CAUSED OR EXACTED BY ACTIVITY P38 MAP KINASA AND / OR NON-REGULATED TNF, SUCH AS INFLAMMATIONS, TUMORS, AIDS AND OTHERS.
PHARMACEUTICAL COMPOSITION INCLUDING AN PDE 2 INHIBITOR, AN E2 SELECTIVE RECEIVER AGONIST AND A CARRIER; AND USE IN THE TREATMENT OF FRACTURE AND / OR OSEO DEFECT (DIV. SOL. 3179-04).
USE OF GABAA INVESTED AGONISTS IN COMBINATION WITH PARTIAL AGONISTS OF THE NICOTINE RECEIVER, ESTRÓGENOS, SELECTIVE MODULATORS OF ESTRÓGENOS OR VITAMIN E, FOR THE TREATMENT OF COGNITIVE DISORDERS.